| Name | Title | Contact Details |
|---|
AIT Laboratories is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Trellus Health is the leader in resilience-driven care for complex chronic conditions. Our multidisciplinary connected health solution coordinates expert-driven personalized care, including clinical and behavioral health, to improve outcomes and reduce costs for patients, employers, and the entire healthcare system.
First Script Network Services is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With a reputation as an innovative provider of quality care, Southwell is a growing, not-for-profit health system serving 12 counties in South Central Georgia. Southwell offers more than 135 physicians with expertise in over 30 specialties. Southwell provides a wide-range of care, including signature services in surgery, oncology, cardiovascular care, women`s health, neurodiagnostics, geriatric psychiatric care, radiology and more. The Main Campus is Tift Regional Medical Center, a 181-bed regional referral hospital located in Tifton. Our Tifton West Campus houses various diagnostic services and the region`s largest multi-specialty clinic. Our Cook County campus is anchored by Southwell Medical, an acute care facility which includes state-of-the-art surgical services and a 12-bed geriatric psychiatric unit. The Cook campus also includes Southwell Health and Rehabilitation, a 95-bed skilled rehabilitation facility.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.